Terisa Jones
Family · Waynesville, NCNPI 1720714330
Payments from drug & device makers
Across 106 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$561
- Otsuka America Pharmaceutical, Inc.$333
- Pfizer$209
- Lilly USA, LLC$180
- Novo Nordisk$112
- AstraZeneca$105
- plus $478 from 11 others
What the payments were for
- Food & beverage$1,977100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $561 |
| Otsuka America Pharmaceutical, Inc. | 17 | $333 |
| Pfizer | 10 | $209 |
| Lilly USA, LLC | 10 | $180 |
| Novo Nordisk | 6 | $112 |
| AstraZeneca | 6 | $105 |
| Exact Sciences | 5 | $81 |
| Merck | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $76 |
| Bayer | 4 | $75 |
| Ironwood Pharmaceuticals, Inc | 3 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$1,977 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $33,531 |
| EliquisApixaban | 35 | $27,482 |
| RybelsusSemaglutide | 14 | $16,651 |
| MounjaroTirzepatide | 11 | $11,070 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 44 | $10,048 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,155 |
| MyrbetriqMirabegron | 12 | $5,024 |
| SynthroidLevothyroxine Sodium | 21 | $1,573 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,059 |
| Omeprazole | 74 | $963 |
| Rosuvastatin Calcium | 40 | $646 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $641 |
| Atorvastatin Calcium | 67 | $628 |
| Escitalopram Oxalate | 39 | $609 |
| Fluticasone Propionate | 40 | $422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $112 | $50,18243 claims |
| PfizerEliquis | $209 | $27,48235 claims |
| Lilly USA, LLCMounjaro | $180 | $11,07011 claims |
| AbbVieSynthroid | $561 | $1,57321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Waynesville
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.